| Literature DB >> 36231510 |
Paulina Mazur-Kurach1, Barbara Frączek1, Andrzej T Klimek2.
Abstract
(1) Background: The aim of this study was to assess the impact of multi-strain probiotic supplementation on the physical capacity and selected health indicators related to the exercise capacity of competitive road cyclists such as body composition, markers of intestinal permeability, pro- and anti-inflammatory markers, and anti-/pro-oxidant potential. (2)Entities:
Keywords: athletes; health; performance; probiotics; sport
Mesh:
Substances:
Year: 2022 PMID: 36231510 PMCID: PMC9566127 DOI: 10.3390/ijerph191912205
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Research process flowchart.
Maximal oxygen uptake (VO2 ma), exercise duration (t), maximum power (Pma), and maximal heart rate (HRmax) during the aerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| VO2ma | baseline | 65.28 * | 6.00 | 1.66 | 58.03 * | 0.52 | 2.92 | |
| 4-weeks | 63.62 * | 5.79 | 1.60 | 58.45 * | 7.99 | 2.22 | ||
| 12-weeks | 65.03 | 5.77 | 1.60 | 60.36 * | 8.38 | 2.33 | ||
| 16-weeks |
| 5.69 | 1.58 |
| 6.69 | 1.86 | ||
| t [min] | baseline | 14.35 | 1.80 | 0.50 | 14.92 | 1.12 | 0.31 | |
| 4-weeks | 15.00 | 1.15 | 0.32 | 14.88 | 1.75 | 0.48 | ||
| 12-weeks | 15.12 | 2.11 | 0.58 | 15.04 | 2.14 | 0.59 | ||
| 16-weeks |
| 2.02 | 0.56 |
| 1.89 | 0.53 | ||
| Pma | baseline | 5.11 | 0.68 | 0.19 | 4.83 | 0.71 | 0.20 | |
| 4-weeks | 5.29 | 0.47 | 0.13 | 4.88 | 0.81 | 0.23 | ||
| 12-weeks | 5.38 | 0.68 | 0.19 | 4.91 | 0.85 | 0.24 | ||
| 16-weeks | 5.36 | 0.60 | 0.17 | 4.86 | 0.79 | 0.22 | ||
| HRmax [bpm] | baseline | 193.3 * | 3.01 | 0.84 | 182.8 * | 7.74 | 2.15 | |
| 4-weeks | 193.8 * | 4.24 | 1.18 | 182.8 * | 7.69 | 2.13 | ||
| 12-weeks | 192.0 * | 6.76 | 1.87 | 184.0 * | 0.47 | 2.90 | ||
| 16-weeks |
| 7.08 | 1.96 |
| 9.36 | 2.60 | ||
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05); # Statistically significant differences compared with the baseline (p < 0.05).
The blood lactate concentrations at baseline, 3, 10, and 20 min post-aerobic testing at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) | |||||
|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | ||
| LA [mmol/L] | baseline | 2.33 | 0.48 | 0.13 | 1.78 | 0.38 | 0.11 |
| 4-weeks | 3.09 | 1.80 | 0.50 | 2.14 | 0.39 | 0.11 | |
| 12-weeks | 2.71 | 1.80 | 0.50 | 1.84 | 0.24 | 0.07 | |
| 16-weeks | 2.34 | 0.87 | 0.24 | 2.57 | 0.64 | 0.18 | |
| LA [mmol/L] | baseline | 13.42 | 1.39 | 0.38 | 12.38 | 2.50 | 0.69 |
| 4-weeks | 14.36 | 1.97 | 0.55 | 13.44 | 3.44 | 0.95 | |
| 12-weeks | 12.39 | 2.51 | 0.70 | 12.95 | 3.03 | 0.84 | |
| 16-weeks | 12.36 | 2.94 | 0.81 | 12.24 | 2.61 | 0.72 | |
| LA [mmol/L] | baseline | 11.12 | 1.25 | 0.35 | 10.26 | 2.74 | 0.76 |
| 4-weeks | 11.67 | 1.74 | 0.48 | 10.03 | 2.65 | 0.73 | |
| 12-weeks | 9.95 | 2.87 | 0.80 | 9.48 | 3.49 | 0.97 | |
| 16-weeks |
| 2.76 | 0.76 | 10.22 | 2.86 | 0.79 | |
| LA [mmol/L] | baseline | 7.16 | 1.53 | 0.43 | 6.53 | 2.54 | 0.70 |
| 4-weeks | 8.55 | 2.15 | 0.60 | 7.11 | 2.22 | 0.62 | |
| 12-weeks | 6.14 | 1.85 | 0.51 | 6.02 | 2.86 | 0.79 | |
| 16-weeks |
| 2.16 | 0.60 | 6.82 | 2.43 | 0.67 | |
x—mean; SD—standard deviation; SE—standard error; # Statistically significant differences compared with the baseline (p < 0.05).
The subjective feeling of fatigue according to the Borg scale during the aerobic test.
| Measurement | Probiotic Group (P) | Control Group (C) |
| ||||
|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | ||
| baseline | 19.38 | 0.48 | 0.13 | 19.30 | 0.72 | 0.20 | |
| 4-weeks | 19.30 | 0.6 | 0.16 | 19.53 | 0.49 | 0.13 | |
| 12-weeks | 19.00 | 0.55 | 0.15 | 19.07 | 0.88 | 0.22 | |
| 16-weeks |
| 0.6 | 0.16 |
| 0.73 | 0.20 | |
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05).
Global workload Wglob. [kJ], level of maximal anaerobic power MAP [W], relative-to-body-weight average anaerobic power MAP [W∙kg−1], average power P [W], relative-to-body-weight average power P [W∙g−1], mean time to achieve maximal anaerobic power to [s], and time to maintain maximal anaerobic power tu [s] at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| Wglob. [kJ] | baseline | 12.59 | 1.18 | 0.33 | 13.84 | 1.49 | 0.41 | |
| 4-weeks | 12.69 | 1.10 | 0.31 | 13.91 | 1.50 | 0.42 | ||
| 12-weeks | 12.78 | 0.98 | 0.27 | 13.63 | 1.74 | 0.48 | ||
| 16-weeks | 12.83 | 0.07 | 0.30 | 13.64 | 1.69 | 0.47 | ||
| MAP [W] | baseline | 742.7 | 72.31 | 2 0.05 | 816.6 | 99.44 | 27.58 | |
| 4-weeks | 753.0 | 69.46 | 19.27 | 817.6 | 102.8 | 28.51 | ||
| 12-weeks | 746.1 | 61.83 | 17.15 | 791.6 | 108.5 | 30.08 | ||
| 16-weeks | 742.0 | 65.52 | 18.17 | 801.1 | 115.4 | 22.01 | ||
| MAP [W·kg−1] | baseline | 11.69 | 1.09 | 0.30 | 11.67 | 2.56 | 0.10 | |
| 4-weeks | 11.71 | 1.05 | 0.2 | 11.61 | 0.5 | 0.24 | ||
| 12-weeks | 11.60 | 0.79 | 0.22 | 11.77 | 2.60 | 0.31 | ||
| 16-weeks | 11.66 | 0.76 | 0.21 | 11.84 | 2.61 | 0.29 | ||
| P [W] | baseline | 629.5 | 58.96 | 16.35 | 692.1 | 74.44 | 20.65 | |
| 4-weeks | 634.4 | 55.40 | 15.37 | 695.6 | 75.07 | 20.82 | ||
| 12-weeks | 638.7 | 48.90 | 13.56 | 680.4 | 85.50 | 23.71 | ||
| 16-weeks | 641.5 | 53.66 | 14.88 | 682.5 | 85.97 | 23.85 | ||
| P [W·kg−1] | baseline | 9.92 | 0.93 | 0.26 | 9.75 | 0.46 | 0.13 | |
| 4-weeks | 9.87 | 0.85 | 0.23 | 9.89 | 0.51 | 0.14 | ||
| 12-weeks | 9.93 | 0.63 | 0.17 | 9.55 | 0.69 | 0.19 | ||
| 16-weeks | 10.00 | 0.66 | 0.18 | 9.66 | 0.63 | 0.17 | ||
| to [s] | baseline | 4.26 | 0.76 | 0.21 | 3.83 | 0.48 | 0.13 | |
| 4-weeks | 3.94 | 0.60 | 0.17 | 3.78 | 0.25 | 0.07 | ||
| 12-weeks | 3.91 | 0.45 | 0.13 | 3.59 | 0.33 | 0.09 | ||
| 16-weeks | 4.01 | 0.58 | 0.16 | 3.67 | 0.27 | 0.08 | ||
| tu [s] | baseline | 3.39 | 0.87 | 0.24 | 3.31 | 0.43 | 0.12 | |
| 4-weeks | 3.16 | 0.67 | 0.19 | 3.16 | 0.30 | 0.08 | ||
| 12-weeks | 3.18 | 0.52 | 0.14 | 3.36 | 0.46 | 0.13 | ||
| 16-weeks | 3.42 | 0.45 | 0.12 | 3.04 | 0.67 | 0.19 | ||
x—mean; SD—standard deviation; SE—standard error.
The blood lactate concentrations at baseline, 3, 10, and 20 min post-exercise for the anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) | |||||
|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | ||
| LA [mmol/L] | baseline | 2.18 | 0.31 | 0.09 | 1.92 | 0.52 | 0.14 |
| 4-weeks | 2.06 | 0.41 | 0.11 | 2.09 | 0.53 | 0.15 | |
| 12-weeks | 2.13 | 0.49 | 0.13 | 2.12 | 0.44 | 0.12 | |
| 16-weeks | 1.76 | 0.44 | 0.12 | 2.03 | 0.43 | 0.12 | |
| LA [mmol/L] | baseline | 11.14 | 1.86 | 0.52 | 11.59 | 1.98 | 0.55 |
| 4-weeks | 13.16 | 2.11 | 0.59 | 11.93 | 3.01 | 0.83 | |
| 12-weeks | 10.43 | 1.63 | 0.45 | 10.21 | 2.26 | 0.63 | |
| 16-weeks |
| 0.87 | 0.24 | 11.52 | 2.28 | 0.63 | |
| LA [mmol/L] | baseline | 11.23 | 1.88 | 0.52 | 11.71 | 2.46 | 0.68 |
| 4-weeks | 11.51 | 1.81 | 0.50 | 10.45 | 3.32 | 0.92 | |
| 12-weeks | 9.34 | 1.50 | 0.42 | 8.76 | 2.10 | 0.58 | |
| 16-weeks |
| 1.63 | 0.45 | 9.30 | 2.09 | 0.58 | |
| LA [mmol/L] | baseline | 7.55 | 1.85 | 0.51 | 8.26 | 1.60 | 0.44 |
| 4-weeks | 7.16 | 2.09 | 0.58 | 7.80 | 2.17 | 0.60 | |
| 12-weeks | 6.60 | 1.25 | 0.35 | 7.45 | 2.13 | 0.59 | |
| 16-weeks |
| 1.22 | 0.34 | 7.65 | 1.91 | 0.53 | |
x—mean; SD–standard deviation; SE—standard error; # Statistically significant differences compared with the baseline (p < 0.05).
Body weight, BMI, fat-free mass (FFM), fat mass (FM), and muscle mass (MM) at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) | |||||
|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | ||
| Body weight [kg] | baseline | 63.52 | 3.77 | 1.05 | 65.17 | 8.44 | 2.34 |
| 4-weeks | 63.97 | 4.26 | 1.18 | 64.14 | 7.55 | 2.09 | |
| 12-weeks | 64.14 | 4.41 | 1.22 | 65.92 | 7.35 | 2.04 | |
| 16-weeks | 63.92 | 4.15 | 1.15 | 66.52 | 7.45 | 2.07 | |
| BMI [kg/m2] | baseline | 20.80 | 1.11 | 0.31 | 21.79 | 2.04 | 0.57 |
| 4-weeks | 20.95 | 1.33 | 0.37 | 21.18 | 1.90 | 0.53 | |
| 12-weeks | 20.92 | 1.20 | 0.33 | 21.77 | 1.47 | 0.41 | |
| 16-weeks | 21.06 | 1.03 | 0.29 | 21.97 | 1.26 | 0.35 | |
| FFM [%] | baseline | 92.15 | 2.60 | 0.72 | 90.59 | 5.17 | 1.43 |
| 4-weeks | 92.63 | 3.75 | 1.04 | 91.00 | 5.86 | 1.63 | |
| 12-weeks | 93.00 | 13.33 | 3.70 | 89.60 | 6.47 | 1.79 | |
| 16-weeks | 96.10 | 3.27 | 0.91 | 90.11 | 6.12 | 1.70 | |
| FM [%] | baseline | 7.85 | 2.60 | 0.72 | 9.41 | 5.17 | 1.43 |
| 4-weeks | 7.37 | 3.75 | 1.04 | 9.00 | 5.97 | 1.66 | |
| 12-weeks | 7.00 | 3.95 | 1.10 | 9.40 | 6.47 | 1.79 | |
| 16-weeks | 5.9 | 2.82 | 0.78 | 9.89 | 6.12 | 1.70 | |
| MM [%] | baseline | 51.95 * | 2.28 | 0.63 | 47.78 * | 8.66 | 2.40 |
| 4-weeks | 53.40 * | 2.82 | 0.78 | 48.95 * | 9.33 | 2.59 | |
| 12-weeks | 55.00 * | 4.06 | 1.13 | 53.09 * | 4.39 | 1.22 | |
| 16-weeks |
| 6.19 | 1.72 | 52.83 * | 4.02 | 1.12 | |
x—mean; SD—standard deviation; SE—standard error. * statistically significant intergroup differences (p < 0.05); # statistically significant differences compared with the initial value (p < 0.05).
Figure 2Concentration of zonulin in stool at follow-up measurements during supplementation intervention. * Statistically significant intergroup differences (p < 0.05); # statistically significant differences compared with the initial value (p < 0.05).
Figure 3Alpha-1-antitrypsin level in the blood serum at follow-up measurements during supplementation intervention. * Statistically significant intergroup differences (p < 0.05) # Statistically significant differences compared with the initial value (p < 0.05).
Figure 4Alfa-1-antytrypsin concentration in the stool sample at follow-up measurements points during supplementation intervention. * statistically significant intergroup differences (p < 0.05).
Immunoglobulin A (IgA) concentration in blood serum at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| Ig A [mg/mL] | baseline | 1.85 | 1.13 | 0.31 | 1.59 | 0.59 | 0.16 | |
| 4-weeks | 1.88 | 1.01 | 0.28 | 1.58 | 0.58 | 0.16 | ||
| 12-weeks | 1.95 | 1.00 | 0.28 | 1.58 | 0.60 | 0.17 | ||
| 16-weeks | 2.03 # | 0.98 | 0.27 | 1.61 | 0.60 | 0.17 | ||
x—mean; SD—standard deviation; SE—standard error; # Statistically significant differences compared with the baseline (p < 0.05).
The mean TNF-α values during pre- and post-aerobic and during pre- and post- anaerobic tests at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| TNF-α | baseline | 9.65 * | 5.84 | 1.62 | 14.26 * | 5.32 | 1.47 | |
| 4-weeks | 14.29 * | 7.71 | 2.14 | 20.59 * | 5.60 | 1.55 | ||
| 12-weeks | 9.54 * | 4.08 | 1.13 | 15.26 * | 7.58 | 2.10 | ||
| 16-weeks | 10.15 * | 2.76 | 0.77 | 11.72 * | 8.11 | 2.25 | ||
| TNF-α | baseline |
| 5.90 | 1.64 | 11.28 * | 4.21 | 1.17 | |
| 4-weeks |
| 6.01 | 1.67 | 25.32 * | 10.51 | 2.92 | ||
| 12-weeks |
| 3.89 | 1.08 | 20.62 * | 10.96 | 3.04 | ||
| 16-weeks |
| 4.30 | 1.19 | 14.74 * | 10.36 | 2.87 | ||
| TNF-α | baseline | 7.34 | 3.05 | 0.85 | 13.49 | 8.65 | 2.40 | |
| 4-weeks | 10.71 | 5.08 | 1.41 | 10.35 | 1.91 | 0.53 | ||
| 12-weeks | 8.85 | 4.12 | 1.14 | 10.55 | 2.81 | 0.78 | ||
| 16-weeks | 9.42 | 5.09 | 1.41 | 9.32 | 3.43 | 0.95 | ||
| TNF-α | baseline |
| 6.37 | 1.77 | 21.71 * | 7.26 | 2.01 | |
| 4-weeks |
| 6.77 | 1.88 | 16.81 * | 8.96 | 2.48 | ||
| 12-weeks |
| 2.89 | 0.80 | 14.74 * | 9.97 | 2.76 | ||
| 16-weeks |
| 3.41 | 0.95 | 13.53 * | 11.02 | 3.06 | ||
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05) # Statistically significant differences compared with the initial value (p < 0.05).
The concentration of 1β (IL-1 β) pre- and post-aerobic tests and pre- and post- anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) | |||||
|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | ||
| IL-1β [pg/mL] before aerobic test | baseline | 0.065 | 0.041 | 0.022 | 0.109 | 0.021 | 0.041 |
| 16 weeks | 0.094 | 0.056 | 0.033 | 0.103 | 0.060 | 0.039 | |
| IL-1β [pg/mL] | baseline | 0.084 | 0.024 | 0.029 | 0.083 | 0.052 | 0.031 |
| 16 weeks | 0.110 | 0.064 | 0.038 | 0.082 | 0.228 | 0.031 | |
| IL-1β [pg/mL] before anaerobic test | baseline | 0.107 | 0.051 | 0.037 | 0.066 | 0.030 | 0.025 |
| 16 weeks | 0.094 | 0.056 | 0.033 | 0.075 | 0.015 | 0.028 | |
| IL-1β [pg/mL] | baseline | 0.097 | 0.029 | 0.034 | 0.071 | 0.002 | 0.026 |
| 16 weeks | 0.110 | 0.064 | 0.038 | 0.099 | 0.060 | 0.037 | |
x—mean; SD—standard deviation; SE—standard error.
The concentration of Interleukin 6 (IL-6) pre- and post-aerobic test and pre- and post-anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| IL-6 [pg/mL] | baseline | 1.18 | 0.41 | 0.11 | 1.09 | 0.17 | 0.05 | |
| 16-weeks | 0.80 | 0.27 | 0.08 | 1.23 | 0.46 | 0.13 | ||
| IL-6 [pg/mL] | baseline | 1.71 | 0.72 | 0.20 | 1.14 | 0.18 | 0.05 | |
| 16-weeks | 1.76 | 1.00 | 0.28 | 1.65 | 0.24 | 0.07 | ||
| IL-6 [pg/mL] | baseline | 1.20 * | 0.37 | 0.10 | 2.61 * | 2.26 | 0.63 | |
| 16-weeks | 0.86 * | 0.19 | 0.05 | 1.06 *# | 0.21 | 0.06 | ||
| IL-6 [pg/mL] | baseline | 1.47 | 0.45 | 0.12 | 1.57 | 0.63 | 0.17 | |
| 16-weeks | 0.97 # | 0.27 | 0.08 | 1.05 # | 0.31 | 0.09 | ||
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05); # Statistically significant differences compared with the initial value (p < 0.05).
The concentration of Interleukin 8 (IL-8) pre- and post-aerobic test and pre- and post- anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| IL-8 [pg/mL] | baseline | 6.75 * | 1.12 | 0.31 | 4.70 * | 1.40 | 0.39 | |
| 16-weeks | 7.68 | 1.80 | 0.50 | 7.10 # | 1.10 | 0.30 | ||
| IL-8 [pg/mL] | baseline | 7.48 | 3.20 | 0.89 | 5.41 | 1.23 | 0.34 | |
| 16-weeks | 8.48 | 1.36 | 0.38 | 8.73 # | 2.50 | 0.69 | ||
| IL-8 [pg/mL] | baseline | 7.38 | 2.65 | 0.73 | 6.70 | 1.00 | 0.28 | |
| 16-weeks | 6.87 | 1.39 | 0.39 | 6.57 | 1.03 | 0.28 | ||
| IL-8 [pg/mL] | baseline | 6.71 | 1.39 | 0.38 | 6.11 | 0.41 | 0.11 | |
| 16-weeks | 6.65 | 2.02 | 0.56 | 5.48 | 2.38 | 0.66 | ||
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05) # Statistically significant differences compared with the initial value (p < 0.05).
The concentration of Interleukin 10 (IL-10) pre- and post-aerobic test and pre- and post- anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| IL-10 [pg/mL] | baseline | 0.48 | 0.37 | 0.10 | 0.54 | 0.25 | 0.07 | |
| 16-weeks | 0.45 | 0.28 | 0.08 | 0.36 | 0.19 | 0.05 | ||
| IL-10 [pg/mL] | baseline | 0.76 | 0.72 | 0.20 | 0.57 | 0.35 | 0.10 | |
| 16-weeks | 0.47 *# | 0.56 | 0.15 | 0.29 * | 0.11 | 0.03 | ||
| IL-10 [pg/mL] | baseline | 0.70 * | 0.43 | 0.12 | 0.39 * | 0.18 | 0.05 | |
| 16-weeks | 0.44 | 0.25 | 0.07 | 0.35 | 0.19 | 0.05 | ||
| IL-10 [pg/mL] | baseline | 0.54 * | 0.33 | 0.09 | 0.31 * | 0.18 | 0.05 | |
| 16-weeks | 0.48 * | 0.34 | 0.09 | 0.29 * | 0.14 | 0.04 | ||
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05); # Statistically significant differences compared with the initial value (p < 0.05).
Total oxidative status (TOS) of the blood plasma pre- and post-aerobic test and pre- and post- anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| TOS—before aerobic test | baseline | 352.9 | 226.6 | 62.85 | 562.9 | 406.4 | 112.7 | |
| 4-weeks | 536.6 | 266.9 | 74.02 | 624.13 | 1786 | 495.4 | ||
| 12-weeks | 492.4 | 192.3 | 53.34 | 480.9 | 40.30 | 11.18 | ||
| 16-weeks | 498.6 | 242.4 | 67.23 | 625.1 | 365.6 | 101.4 | ||
| TOS—after aerobic test | baseline | 546.9 | 284.7 | 78.96 | 757.1 | 197.7 | 54.83 | |
| 4-weeks | 616.0 | 318.5 | 88.34 | 620.13 | 340.0 | 94.29 | ||
| 12-weeks | 1023 | 722.7 | 200.4 | 957.3 | 370.2 | 102.7 | ||
| 16-weeks | 692.1 | 470.9 | 130.6 | 770.3 | 153.8 | 42.65 | ||
| TOS—before anaerobic test | baseline | 663.7 * | 433.3 | 120.2 | 783.9 * | 272.3 | 75.52 | |
| 4-weeks | 497.7 * | 266.7 | 73.97 | 711.2 * | 280.0 | 77.67 | ||
| 12-weeks | 536.8 * | 247.7 | 68.69 | 652.5 * | 189.9 | 52.66 | ||
| 16-weeks | 484.6 *# | 235.8 | 65.41 | 918.1 * | 295.6 | 81.98 | ||
| TOS—after anaerobic test | baseline | 643.1 * | 391.5 | 108.6 | 740.9 * | 245.3 | 68.04 | |
| 4-weeks | 402.8 * | 191.2 | 53.03 | 1635 * | 1426 | 395.7 | ||
| 12-weeks | 625.1 | 568.7 | 157.7 | 662.6 | 271.6 | 75.32 | ||
| 16-weeks | 435.9 *# | 256.2 | 71.06 | 751.4 * | 292.6 | 81.14 | ||
x—mean; SD—standard deviation; SE—standard error; * Statistically significant intergroup differences (p < 0.05); # Statistically significant differences compared with the initial value (p < 0.05).
Total anti-oxidant (TAS) status of the blood plasma pre- and post-aerobic test and pre- and post- anaerobic test at follow-up measurements during supplementation intervention.
| Indicator/Measurement | Probiotic Group (P) | Control Group (C) |
| |||||
|---|---|---|---|---|---|---|---|---|
|
| SD | SE |
| SD | SE | |||
| TAS—before aerobic test | baseline | 302.3 | 36.39 | 10.09 | 319.6 | 34.95 | 9.69 | |
| 4-weeks | 305.7 | 30.29 | 8.40 | 321.2 | 28.91 | 8.02 | ||
| 12-weeks | 302.0 | 50.68 | 14.06 | 313.7 | 27.77 | 7.70 | ||
| 16-weeks | 303.7 | 29.58 | 8.20 | 289.1 | 31.91 | 8.85 | ||
| TAS—after aerobic test | baseline | 331.3 | 39.04 | 10.83 | 326.5 | 33.13 | 9.19 | |
| 4-weeks | 307.1 | 38.83 | 10.77 | 294.8 | 36.01 | 9.99 | ||
| 12-weeks | 338.4 | 51.21 | 14.20 | 290.9 | 27.28 | 7.56 | ||
| 16-weeks | 299.0 | 47.75 | 13.24 | 304.5 | 9.71 | 2.69 | ||
| TAS—before anaerobic test | baseline | 302.8 | 34.02 | 9.44 | 343.4 | 22.03 | 6.11 | |
| 4-weeks | 308.9 | 40.29 | 11.17 | 309.4 | 37.06 | 10.28 | ||
| 12-weeks | 291.0 | 45.77 | 12.69 | 298.2 | 51.16 | 14.19 | ||
| 16-weeks | 279.8 | 44.12 | 12.24 | 292.7 | 52.30 | 14.51 | ||
| TAS—after anaerobic test | baseline | 328.7 | 59.28 | 16.44 | 329.7 | 57.11 | 15.84 | |
| 4-weeks | 314.5 | 40.79 | 11.31 | 363.3 | 22.66 | 6.28 | ||
| 12-weeks | 308.3 | 56.69 | 15.72 | 304.7 | 45.20 | 12.54 | ||
| 16-weeks | 301.2 | 14.71 | 4.08 | 299.9 | 44.11 | 12.23 | ||
x—mean; SD—standard deviation; SE—standard error.